Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

What is a Nervous System?01:25

What is a Nervous System?

105.2K
Overview
105.2K
The Parasympathetic Nervous System01:14

The Parasympathetic Nervous System

115.9K
Overview
115.9K
The Sympathetic Nervous System01:25

The Sympathetic Nervous System

104.0K
Overview
104.0K
Secondary Active Transport01:55

Secondary Active Transport

138.1K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
138.1K
The Central Dogma01:25

The Central Dogma

140.0K
Overview
140.0K
Secondary Healthcare System01:11

Secondary Healthcare System

2.1K
Secondary healthcare is offered by a specialist, generally in hospitals or clinics for patients referred by primary healthcare providers. It occurs when a person has an illness or injury that requires specific medical care. Secondary care is often referred to as acute care. Secondary care can range from uncomplicated care to repair a minor laceration or treat a strep throat infection to more complicated emergent care, such as treating a head injury sustained in an automobile accident. Whatever...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of the diagnosis-to-treatment interval on the survival of patients with CD5-positive diffuse large B-cell lymphoma.

Annals of hematology·2026
Same author

Case series of long-term responders to pralatrexate in peripheral T-cell lymphoma.

Journal of clinical and experimental hematopathology : JCEH·2025
Same author

Treatments and Outcomes of Newly Diagnosed CD5-Positive Diffuse Large B-Cell Lymphoma: A Multi-Institutional Observational Study.

Hematological oncology·2025
Same author

Wearable EMG Measurement Device Using Polyurethane Foam for Motion Artifact Suppression.

Sensors (Basel, Switzerland)·2024
Same author

Investigation of biomarkers to predict outcomes in allogeneic hematopoietic stem cell transplantation.

Cytotherapy·2024
Same author

Pretransplantation Inflammatory and Nutritional Status in Elderly Allogeneic Hematopoietic Stem Cell Transplantation: Prognostic Value of C-Reactive Protein-to-Albumin Ratio.

Transplantation and cellular therapy·2024

Related Experiment Video

Updated: Feb 10, 2026

Optical Clearing of the Mouse Central Nervous System Using Passive CLARITY
10:28

Optical Clearing of the Mouse Central Nervous System Using Passive CLARITY

Published on: June 30, 2016

14.1K

Secondary central nervous system lymphoma.

Naoto Tomita1, Fumio Kodama, Heiwa Kanamori

  • 1Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan. cavalier@ch-yamate.dlenet.com

International Journal of Hematology
|August 24, 2006
PubMed
Summary

Secondary central nervous system lymphoma (SCNSL) involves the brain or spinal cord. Early diagnosis and risk factor identification are crucial for effective treatment and preventing recurrence in lymphoma patients.

More Related Videos

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
14:55

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Published on: May 12, 2013

61.9K
Isolation of Mononuclear Cells from the Central Nervous System of Rats with EAE
20:51

Isolation of Mononuclear Cells from the Central Nervous System of Rats with EAE

Published on: December 3, 2007

16.8K

Related Experiment Videos

Last Updated: Feb 10, 2026

Optical Clearing of the Mouse Central Nervous System Using Passive CLARITY
10:28

Optical Clearing of the Mouse Central Nervous System Using Passive CLARITY

Published on: June 30, 2016

14.1K
Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
14:55

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Published on: May 12, 2013

61.9K
Isolation of Mononuclear Cells from the Central Nervous System of Rats with EAE
20:51

Isolation of Mononuclear Cells from the Central Nervous System of Rats with EAE

Published on: December 3, 2007

16.8K

Area of Science:

  • Hematology
  • Neurology
  • Oncology

Background:

  • Secondary central nervous system lymphoma (SCNSL) is CNS involvement not apparent at initial systemic lymphoma treatment.
  • Accurate diagnosis of SCNSL has improved with cerebrospinal fluid polymerase chain reaction and flow cytometry.
  • Understanding SCNSL incidence and risk factors is vital for patient management.

Purpose of the Study:

  • To review current knowledge on secondary central nervous system lymphoma in adults.
  • To identify key risk factors associated with SCNSL development.
  • To summarize treatment strategies and the role of central nervous system prophylaxis.

Main Methods:

  • Review of literature on patients treated without central nervous system prophylaxis to assess SCNSL incidence.
  • Analysis of risk factors including serum lactate dehydrogenase, extranodal sites, disease stage, and International Prognostic Index.
  • Evaluation of treatment modalities and central nervous system prophylaxis strategies.

Main Results:

  • Key risk factors for SCNSL include elevated serum lactate dehydrogenase, multiple extranodal sites, advanced stage, high age-adjusted International Prognostic Index, and testicular involvement.
  • Histologic aggressiveness is a general indicator of SCNSL risk.
  • Newer treatments like stem cell transplantation and intrathecal rituximab are in clinical use.

Conclusions:

  • Central nervous system prophylaxis aims to prevent isolated CNS recurrence and is fundamental for highly aggressive lymphomas.
  • CNS-active strategies are increasingly recognized for aggressive lymphomas and can complement other treatments.
  • Despite poor prognosis, CNS involvement management is improving lymphoma outcomes.